CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
2 research outputs found
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate
Author
Brian J. Druker
Carolyn Blasdel
+6Â more
Gwen Kurilik
Melanie Farnsworth
Michael E. O'Dwyer
Michael J. Mauro
Motomi Mori
Yi-Ching Hsieh
Publication venue
'American Society of Hematology'
Publication date
Field of study
No full text
Crossref
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML
Author
Ahuja
Bernstein
+30Â more
Boultwood
Brian J. Druker
Brummendorf
Clift
Daley
Druker
Ellen Magenis
Griesshammer
Gwen Kurilik
Kantarjian
Kantarjian
Kantarjian
Kreil
Lugo
Majlis
McGlave
Michael E. O'Dwyer
Michael J. Mauro
Motomi Mori
Nowell
O'Dwyer
Reiffers
Renaud Capdeville
Rowley
Sokal
Speck
Susan Olson
Suzanne Balleisen
Talpaz
World Health Organization Classification of Tumours
Publication venue
'American Society of Hematology'
Publication date
Field of study
No full text
Crossref